G protein coupled receptors (GPCRs) are known to initiate a plethora of signaling pathways in vitro. However, it is unclear which of these pathways are engaged to mediate physiological responses. Here we examine the distinct roles of Gq/11-dependent signaling and receptor phosphorylation-dependent signaling in bronchial airway contraction and lung function regulated through the M3-muscarinic acetylcholine receptor (M3-mAChR). By employing a genetically-engineered mouse expressing a G protein biased M3-mAChR mutant we reveal the first evidence of a novel role for M3-mAChR phosphorylation in bronchial smooth muscle contraction in health and in a disease state with relevance to human asthma. Furthermore, this mouse model can be used to distinguish the physiological responses that are regulated by M3-mAChR phosphorylation (which include control of lung function), from those that are down-stream of G protein signaling. In this way we present a novel approach by which to predict the physiological/therapeutic outcome of M3-mAChR biased ligands with important implications for drug discovery.
Introduction
Airflow in the lung is limited by vagally derived acetylcholine that mediates airway smooth muscle (ASM) contraction primarily via activation of M3-mAChRs (1) . In both asthma and chronic obstructive pulmonary disease (COPD) this activity can be upregulated leading to bronchoconstriction and impaired lung function (1) thus explaining the therapeutic benefits provided by anticholinergics, such as tiotropium bromide (2) .
M3-mAChRs can mediate ASM contraction through both calcium-dependent and calcium-independent mechanisms (1). The calcium-dependent mechanism is centred on G q/11 -mediated phospholipase C activation generating inositol 1,4,5, trisphosphate that mobilizes calcium from the sarcoplasmic reticulum together with promoting extracellular calcium entry that ultimately results in a rise in intracellular calcium, activation of myosinlight chain kinase and the phosphorylation of myosin leading to contraction (3) . In contrast, the mechanism by which M3-mAChR mediates calcium-independent ASM contraction is via activation of the small GTPase RhoA, which in turn activates Rho-kinase. The phosphorylation of myosin-light chain phosphatase by Rhokinase decreases enzymatic activity, which results in higher levels of phosphorylated myosin and smooth muscle contraction (3) (4) (5) . Although GPCR activation of RhoA is generally considered to be via G q/11 and G 12/13 hetero-trimeric G proteins (6) the mechanism by which M3-mAChR activates the RhoA pathway is unclear with some indicating that this might proceed in a G proteinindependent manner and possibly involve a direct interaction between the receptor and RhoA (7) . The prominence of the calcium-independent pathway in excessive airway narrowing (i.e. bronchial hyper-responsiveness) previously observed in animal models of allergic bronchial asthma have prompted the suggestion that inhibiting the M3-mAChR pathways leading to RhoA activation might be of therapeutic potential (8, 9) .
GPCRs become rapidly phosphorylated following agonist stimulation and this results in the recruitment of adaptor arrestin proteins that firstly uncouple receptors from their cognate G proteins and secondly act as signaling scaffolds to drive G proteinindependent signaling (10) . The activation of RhoA-signaling has been identified as one of those pathways regulated by receptor phosphorylation/arrestin-dependent signaling (11, 12) . Since we have shown previously that the M3-mAChR is multiply phosphorylated following agonist stimulation (13) and that removal of the phosphorylation sites on the receptor results in the uncoupling of Significance Studies in transfected cells have established that GPCRs activate a number of intracellular signaling pathways; however which of these are physiologically important is unclear. Here we use a genetically engineered mouse to demonstrate a novel role for muscarinic receptor (M3-mAChR) phosphorylation in airway constriction, with implications for human respiratory disease including asthma and COPD. Combining this finding with other M3-mAChR physiological responses, we generate a map of responses that are down-stream of G proteindependent signaling or receptor phosphorylation-dependent signaling. Such a map predicts the outcome of novel biased GPCR drugs designed to preferentially drive receptor signaling toward pathways that improve therapeutic efficacy whilst minimizing toxic/adverse outcomes and provides a fundamental approach to the rational design of next generation GPCRbased therapies. Fig. 1 . Characterization of M3-mAChR expression and calcium signaling in the airways of Wild Type and M3-KI mice. A. Illustration of the BRETbased biosensor to measure G protein coupling where various donor RlucII Gα-subunits can be transfected with an acceptor GFP 10-Gγ1-subunit together with the M3-mAChR. B-C. Cells were transfected with the BRET biosensor consisting of various Rluc-Gα-subunits. Change in BRET signal following receptor stimulation with carbachol (100 μM) in cells expressing the wild type (B) or phospho-deficient M3-mAChR (C). Data represents the mean ±SEM of three independent experiments. D. M3-mAChR (green) and smooth muscle α-actin immune-reactivity (red) in the airways of wild type, M3-KO and M3-KI mice. DAPI (blue) was used to stain nuclei, and overlaid images are shown to the right. mean Emax values calculated from the above PCLS concentrationresponse curves (n=6 in each group). E-F. In PCLS from wild type and M3-KI mice, calcium responses following acetylcholine (100 μM) stimulation were evaluated. Shown are; E. three representative airway responses from PCLS derived from wild type mice and F. three representative airway responses from PCLS derived from M3-KI mice. G. Average (± SEM) peak calcium responses from representative airways shown in E and F (all responsive singlecells from each airway were included in the analysis). Data show is the mean ±SEM and analyzed using unpaired T test, ***P<0.001.
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Fig. 3.
M3-mAChR mediated airway smooth muscle contraction is dependent on receptor phosphorylation-dependent coupling to RhoA signalingA.An illustration of the FRET-based biosensor used to detect activated RhoA (GTP-bound). B. Rho activity in CHO cells expressing the wild type or the phospho-deficient M3-mAChR mutant in response to carbachol (CCh). Data represents the mean ± SEM (n=4). Data were analyzed using a twoway ANOVA; *P<0.05, **P<0.01. C-D. Phospho-myosin light chain 2 (Ser-19) (green) and smooth muscle α-actin (red) immune-reactivity in the airways of wild type (C) or M3-KI (D) mice stimulated with vehicle or CCh (100 μM; 10 min). DAPI (blue) was used to stain nuclei, and overlaid images are shown to the right. Also shown is an image of the same airway using an x63 objective. E-G. Effect of Rho-kinase inhibitor H1152 on contractile responses in wild type PCLS. E. Mean concentration-response curves to CCh in wild-type PCLS pre-treated with vehicle or H1152 (100 nM, 45 min pre-incubation). F. Mean pEC50 and G. mean Emax values calculated from the above PCLS CCh concentration-response curves in the presence and absence of H1152 (n=12 in vehicle treated and n=17 in H1152 treated PCLS). Data in E-G were analyzed using unpaired T test, ***P<0.001. H-K. Effects of the Gq-inhibitor, FR900359, on CCh (100 μM) stimulated calcium responses and bronchoconstriction in PCLS from wild type mice. H. Average (± SEM) peak calcium responses stimulated by CCh after pre-incubation with increasing concentrations of FR900359 (0.3 nM-300 nM; 30 min). I. Representative examples of CChinduced bronchoconstriction in PCLS from wild type mice under control conditions (left) or following pre-incubation with 30 nM FR900359 (right). J. Mean contractile response to CCh in wild type PCLS following pre-incubation with FR900359 (30 nM; 30 min), expressed as a percentage of CCh-stimulated maximum contraction in control slices. K. Phospho-myosin light chain 2 (Ser-19) (green) and smooth muscle α-actin (red) immune-reactivity in PCLS from wild type mice stimulated with CCh (100 μM; 10 min) after pre-incubation with 30 nM FR900359. DAPI (blue) was used to stain nuclei, and an overlaid image is shown to the right. Also shown is an image of the same airway using a x63 objective.
the M3-mAChR from arrestin, and arrestin-dependent processes such as receptor internalization (14, 15) The concentration of acetylcholine required to increase lung resistance (R L ) by 100% (-logPC100) was determined for wild type and M3-KI mice. Data presented in A and B are the mean ± SEM (WT n=10, M3-KI n=13). Data were analyzed using Kruskal-Wallis and Mann Whitney tests; *P<0.05, **P<0.01, ***P<0.001 WT vs. M 3 -KI. C. Airway hyper-responsiveness was induced using ovalbumin sensitization followed by ovalbumin challenge (ovalbumin) in WT and M3-KI mice. Controls were ovalbumin sensitization followed by saline challenge (saline). Lung resistance (R L ) was determined at various ACh concentrations. Data represent the mean ± SEM (WT n=6, M3-KI n=6 independent ASM contraction and through this mechanism regulate lung function and airway hyper-responsiveness.
In addition, we aimed to establish an experimental system whereby we might distinguish between GPCR-mediated physiological responses that are down-stream of G protein dependent signaling from those that are down-stream of receptor phosphorylation/arrestin dependent signaling processes (16, 17) . In this way we might develop an approach by which to predict the physiological action of biased GPCR ligands with important implications for drug discovery.
In order to achieve these dual aims, we employ here a mouse model where the M3-mAChR gene locus has been targeted to express a form of the M3-mAChR that is mutated in its phosphorylation sites (14, 15) . This mutant receptor is uncoupled from phosphorylation-dependent pathways, including the recruitment of arrestin (14) , but maintains coupling to G q/11 -dependent signaling (14, 15) . In this regard, this mutant receptor can be considered as G protein biased. Using this model we determined a novel role for M3-mAChR phosphorylation in the regulation of lung function and in driving allergen-induced airway hyperresponsiveness. In addition, we were able to include this analysis in a map of M3-mAChR physiological responses that lay downstream of receptor phosphorylation/arrestin dependent signaling and in this way provide a predictive model for the action of biased ligands to the M3-mAChR. The data in A, C and D represent the mean ± SEM of n=6-11 mice and were analyzed using a twoway ANOVA; *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. E. Illustration of the physiologically relevant signaling pathways down-stream of the M3-mAChR. Some of the pathways activated by the M3-mAChR in heterologous systems are illustrated (i.e. PLC, ERK, PKD, JNK, PI3-K, Src, RhoA, PLA 2 and p53). In this study we used a mutant mouse strain (M3-KI) expressing a G protein biased variant of the M3-mAChR to assign those physiological responses that were down-stream of either G protein signaling (green arrows) or receptor-phosphorylation and arrestin signaling (orange arrows). F. Such a map also allows for the rational design of biased ligands since our studies present a model by which the physiological/therapeutic outcome of biased ligands can be predicted. Thus, for the M3-mAChR, a ligand that is biased towards receptor-phosphorylation and arrestin signaling would preferentially impact on insulin release, learning and memory and bronchial contraction (orange arrows) whilst having potentially little impact on weight gain, salivary secretion and cell death pathways (grey arrows).
Results
Phosphorylation-deficient M3-mAChR mutant is expressed in airway smooth muscle and coupled normally to Gq-signaling
We have previously established that a mutant of the M3-mAChR, where 15 serine phospho-acceptor sites in the third intracellular loop were mutated to alanine, showed reduced levels of agonist-mediated phosphorylation and significantly attenuated coupling to arrestin and arrestin-dependent signaling whilst maintaining near normal coupling to G q/11 -dependent signaling (14, 15) . Here, we present further evidence that G protein coupling of the phospho-deficient M3-mAChR mutant is normal by evaluating the coupling of both wild type and mutant receptors to 10 different Gα-subunits in a BRET-based live cell assay (18, 19) (Figure 1A) . These experiments demonstrated that the profile of G protein activation between the wild type M3-mAChR and the phospho-deficient mutant was very similar, with both receptor 273  274  275  276  277  278  279  280  281  282  283  284  285  286  287  288  289  290  291  292  293  294  295  296  297  298  299  300  301  302  303  304  305  306  307  308  309  310  311  312  313  314  315  316  317  318  319  320  321  322  323  324  325  326  327  328  329  330  331  332  333  334  335  336  337  338  339 
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types predominantly coupling to Gq (Figure 1B-C) . Importantly, there appeared to be no significant coupling of the M3-mAChR to G 12/13 proteins ( Figure 1B-C) . Control experiments where the receptor was not transfected showed no significant activation of G proteins including Gq (Supplementary Figure S1A,B) . A mutant mouse strain (termed M3-KI) was generated where the M3-mAChR gene locus was modified to express the phosphodeficient M3-mAChR mutant in place of the wild type receptor (14, 15) . The muscarinic receptor expression levels in lungs from M3-KI mice (determined by radio-ligand binding) were not significantly different from that of lungs from wild type mice (Supplementary Figure S2A, B) . Furthermore, the levels of the mutant receptor transcript in the lungs from M3-KI mice were similar to that of the wild type receptor in C57/BL6 mice as determined by RT-PCR (Supplementary Figure S2C) . Using an inhouse antibody to the M3-mAChR we found a normal expression profile of the mutant M3-mAChR in ASM of M3-KI mice as indicated by co-localization of immuno-staining of the receptor and α-actin in airways ( Figure 1E ).
M3-mAChR mediates airway smooth muscle contraction in a receptor phosphorylation-dependent manner
To determine the impact of mutating phosphorylation sites on the M3-mAChR in lung, we used precision cut lung slices (PCLS) to monitor bronchoconstriction (20) . In agreement with previous reports (21), we showed that muscarinic receptor stimulation of PCLS from wild type mice resulted in a concentrationdependent narrowing of the airways (half-maximal response pEC 50 = 5.47±0.06, Emax = 82.47±5.82 (Figure 2A-C) . In comparison, the responsiveness of PCLS from M3-KI mice was significantly reduced both in maximal response and potency (pEC 50 = 4.01±0.06, Emax = 40.79±5.73) (Figure 2A-D) (also see; supplementary videos 1 and 2). Importantly, the coupling of the phospho-deficient M3-mAChR mutant to Gq/calcium signaling in PCLS derived from M3-KI mice was seen to be very similar to that observed in wild type PCLS cultures (Figure 2E-G) . Thus, despite normal coupling to Gq/calcium mobilization the mutant receptor expressed in M3-KI lung showed reduced airway contraction indicating an important role for receptor phosphorylation-dependent signaling in M3-mAChR-mediated ASM contraction.
Since previous studies had established that the RhoApathway mediates calcium-independent ASM contraction (3-5) we investigated the role of RhoA signaling downstream of M3-mAChR phosphorylation. In vitro analysis of RhoA activation using a FRET-based biosensor ( Figure 3A) revealed that the phospho-deficient M3-mAChR mutant coupled with >200 fold lower potency to the RhoA pathway (pEC 50 = 5.41±0.63) than the wild type receptor (pEC 50 = 7.74±0.17) (Figure 3B) . Activation of the RhoA pathway ultimately results in the phosphorylation of myosin light chain (MLC) and smooth muscle contraction (3) (4) (5) . Staining for phosphorylation of MLC on serine-19 showed pronounced MLC phosphorylation in the ASM in PCLS from wild type animals in both the basal state and following carbachol stimulation ( Figure 3C ). In contrast, ASM in PCLS from M3-KI mice showed substantially less MLC phosphorylation (Figure 3D ) a result consistent with reduced activation of RhoA signalling in M3-KI airways. Furthermore, the RhoA-kinase inhibitor, H1152, reduced the maximal M3-mAChR contractile response in PCLS from wild type mice by 43% and the potency of acetylcholine-mediated contraction by >10 fold (pEC 50 reduced from 5.07±0.15 to 3.98±0.13 following H1152 treatment)( Figure  3E-G) . These data indicate that a significant component of the M3-mAChR-mediated ASM contractile response was independent of Gq/calcium signaling but rather was dependent on M3-mAChR phosphorylation and the activation of the RhoApathway.
Consistent with this notion was the fact that inhibition of M3-mAChR-mediated Gq/calcium mobilization in PCLS from wild type mice using the recently characterized Gq inhibitor, FR900359 (22) (Figure 3H and Supplementary Figure S3A, B) did not affect the M3-mAChR-mediated contractile response ( Figure  3H,J) . The concentration of FR900359 used in these experiments (30nM) completely prevented the carbachol-mediated calcium response in PCLS ( Figure 3H ) but had no significant effect on carbachol-mediated smooth muscle contraction (Figure 3I,J) . Importantly, inhibition of Gq/calcium-signalling with FR900359 did not significantly affect the small contractile response seen in PCLS from M3-KI mice in response to carbachol (Supplementary Figure S4A, B) nor did FR900359 appear to affect the level of MLC phosphorylation in PCLS from wild type mice stimulated with carbachol ( Figure 3K ). These data point to RhoA-mediated signaling down-stream of receptor phosphorylation having a prominent role in M3 receptor-mediated ASM contraction.
Lung function and allergen-associated airway hyperresponsiveness is dependent on M3-mAChR phosphorylation
To test if the reduction in contractile response of PCLS obtained from M3-KI mice translated to changes in in vivo lung function, lung resistance in response to acetylcholine challenge in wild type mice and M3-KI mice was monitored. These studies revealed a rightward shift in the potency and a decrease in the maximal response of the lung resistance induced by administration of acetylcholine in M3-KI mice ( Figure 4A ). The decrease in lung resistance in response to acetylcholine in the M3-KI mice was also reflected in a significant increase in the concentration of acetylcholine required to elevate lung resistance by 100% (-logPC 100 )( Figure 4B) .
M3-mAChR signaling through RhoA in ASM has been closely linked with experimentally induced airway hyperresponsiveness in different studies using murine models of allergy (23, 24) . We tested here if the reduced coupling of the phospho-deficient M3-mAChR mutant to RhoA-signaling and the subsequent reduction in ASM contraction observed in M3-KI mice made an impact on allergen induced airway hyperresponsiveness using a murine model of allergic inflammatory airway disease (25) . In these experiments wild type mice sensitized with ovalbumin and challenged with saline (0.9% NaCl) showed an increase in lung resistance to acetylcholine that was significantly augmented in mice sensitized with ovalbumin and challenged with ovalbumin ( Figure 4C ) -a response defined as classical airway hyper-responsiveness (24, 26, 27) . In contrast, M3-KI mice sensitized with ovalbumin and challenged with ovalbumin showed no hyper-responsiveness in response to acetylcholine administration ( Figure 4C) . The lack of hyperresponsiveness following ovalbumin sensitization/challenge in M3-KI mice was also reflected by the lack of change in the -logPC 100 value in M3-KI mice following ovalbumin sensitization/challenge ( Figure 4D) . Hence, the -logPC 100 value fell from 2.38±0.02 in wild type mice sensitized with ovalbumin and challenged with saline to 1.68±0.06 after ovalbumin sensitization and ovalbumin challenge, indicative of airway hyper-responsiveness ( Figure 4D ). In contrast, the -logPC 100 value for the M3-KI mice ovalbumin sensitized and saline challenged (2.64 ± 0.17) was not significantly different from M3-KI mice that had been between ovalbumin sensitized and ovalbumin challenged (2.59 ± 0.06) ( Figure 4D ). These data indicate that M3-mAChR phosphorylation was required in the development of allergen-induced airway hyper-responsiveness.
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Analysis of different inflammatory cell types in the BAL was carried out. Whereas the macrophage levels (Supplementary Figure S5B) were not seen to change following ovalbumin sensitization/challenge of wild type and M3-KI mice, the number of eosinophils (Supplementary Figure S5C) , neutrophils (Supplementary Figure S5D ) and lymphocytes (Supplementary Figure  S5E) were significantly increased, by the same extent, in wild type and M3-KI mice sensitized with ovalbumin and challenged with ovalbumin.
Phosphorylation of the M3-mAChR regulates specific physiological responses
We show here how use of the G protein biased M3-mAChR mutant receptor expressed in M3-KI can be used to define the role of receptor phosphorylation-dependent signaling in bronchial ASM. We reasoned that this approach could be extended to include other M3-mAChR mediated responses and in this way a map of the physiological responses that lay downstream of the two fundamental signaling arms of the M3-mAChR, namely G protein dependent and phosphorylation/arrestindependent signaling, could be generated. To test this hypothesis we compared the M3-mAChR-mediated contraction of bronchial smooth muscle with other M3-mAChR-mediated physiological responses; namely salivary secretion and weight gain.
Previous gene knockout studies established that salivary secretion in response to low doses of the muscarinic partial agonist pilocarpine was almost completely dependent on M3-mAChR (28) . These studies were confirmed here where salivary secretion in response to pilocarpine was significantly reduced in M3-mAChR-knockout mice ( Figure 5A ). In contrast, salivary secretion in response to pilocarpine in M3-KI mice was significantly enhanced when compared to wild type animals ( Figure 5A ). These results indicated that, in contrast to M3-mAChR-mediated contraction of ASM, M3-mAChR-mediated secretion of saliva was independent of receptor phosphorylation signaling but rather was dependent on signaling through Gq-pathways. The slight increase in salivary secretion observed in M3-KI mice may reflect the fact that phosphorylation-dependent mechanisms, that are traditionally considered to desensitize G protein responses, are not in operation in M3-KI mice.
M3-mAChR-knockout mice have also previously been reported to show reduced food intake and decreased body fat (29) . This has been associated with the action of the M3-mAChR on the hypothalamic leptin/melanocortin system (29) . In addition, the M3-mAChR knockout mice showed an increase in both resting and total energy expenditure (oxygen consumption) as well as an increase in the rate of oxidation of fatty acids (30) -phenotypes that have been linked with M3-mAChR regulation of sympathetic flow (30) . Disruption of both of these physiological processes in M3-mAChR knockout mice combine to generate an overall lean phenotype where the mice show reduced total body weight (29, 31) . We confirm these data here by demonstrating that M3-mAChR knockout mice have reduced body weight compared to wild type controls (Figure 5B,C) . In contrast to the M3-mAChR knockout mice, M3-KI mice were slightly, but significantly, heavier than that the of wild type controls (Figure 5B, D) . These data suggest that M3-mAChR signaling via Gq protein is the primary signaling pathway that regulates M3-mAChR metabolic and feeding responses responsible for weight gain.
Combining these data with previously published results (see; discussion) a map of the physiological pathways down-stream of phosphorylation/arrestin signaling and G protein dependent signaling can be generated ( Figure 5E ) that can be used to predict the physiological/therapeutic outcome of biased M3-mAChR ligands ( Figure 5F ).
Discussion
Our study demonstrates a novel role for M3-mAChR phosphorylation in the regulation of lung function and in driving airway hyper-responsiveness, one of the key features of allergic inflammatory airway disease. Our unique observation also highlights the importance of receptor phosphorylation in mediating M3-mAChR-induced ASM contraction via the activation of the RhoA pathway.
Since previous studies had demonstrated a role for RhoA signaling in calcium-independent ASM contraction (3-5), we employed a genetically engineered mouse that expresses a phosphorylation deficient variant of the M3-mAChR (M3-KI) to investigate the possibility that phosphorylation of the M3-mAChR was involved in coupling the receptor to RhoA signaling and through this mechanism to ASM contraction. That this was the case was indicated by; (i) data showing that pharmacological inhibition of Rho-kinase in wild type PLCS pheno-copied the reduced airway contraction response observed in PCLS from M3-KI mice (ii) that the phospho-deficient M3-mAChR showed markedly reduced coupling to RhoA and (iii) that phosphorylation of MLC was significantly reduced in ASM of M3-KI mice. In addition, we used the recently characterized Gq-inhibitor, FR900359 (22) , to demonstrate that M3-mAChR induced calcium mobilization was inhibited by FR900359 while M3-induced airway contraction was not. Because our experimental design measured the overall calcium changes in whole PCLS, we cannot completely exclude a role of compartmentalized changes in Gq-driven calcium signals in the ASM in the regulation of airway contraction as shown by others (32, 33) . Nonetheless, our data are consistent with a recent report demonstrating that muscarinic-mediated contractile responses in human PCLS were less sensitive to FR900359 and therefore lessdependent on calcium than contraction mediated by histamine receptors (36) . Furthermore, knocking down β-arrestin-1 has been recently shown to impair muscarinic-mediated bronchoconstriction (33) demonstrating the complexity surrounding the procontractile pathways coupled to M3-mAChR in ASM. These studies coupled, with our data, support the hypothesis that M3-mAChR phosphorylation mediates activation of RhoA signaling (possibly by arrestin recruitment) that results in increased MLC phosphorylation and ASM contraction. This phosphorylationdependent calcium sensitization process plays a prominent role in M3-mAChR dependent ASM contraction with a minor role played by calcium transient-dependent processes.
It is known that vagally-derived acetylcholine limits airflow by bronchoconstriction mediated by the activation of the M3-mAChR on ASM (1) . If the role for M3-mAChR phosphorylation in ASM contraction identified here is of physiological relevance then it might be expected that the lung function of M3-KI mice would be different from that of wild type mice. We found that airway obstruction (by assessing lung resistance) in response to acetylcholine was significantly reduced in M3-KI mice compared to wild type mice, an observation consistent with the notion that the phosphorylation status of the M3-mAChR is important in regulating baseline cholinergic ASM tone. This observation is in line with studies conducted in healthy volunteers showing a significant improvement in lung function by anticholinergic drugs (2) . Furthermore, in an acute murine model of allergic inflammatory airway disease, which mimics several of the central hallmarks of human bronchial asthma (34), including airway hyper-responsiveness and immune cell lung infiltration, we show that the development of allergen-induced airway hyper-responsiveness to acetylcholine was dependent on M3-mAChR phosphorylation-dependent pathways since sensitized M3-KI mice failed to demonstrate the typically enhanced airway hyper-responsiveness. Thus, both normal and pathophysiological lung function in M3-KI mice was significantly different from wild type mice indicating an important role for M3-mAChR   545  546  547  548  549  550  551  552  553  554  555  556  557  558  559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578  579  580  581  582  583  584  585  586  587  588  589  590  591  592  593  594 Submission PDF phosphorylation in the regulation of airway narrowing in health and disease states.
The mechanisms by which allergen-exposed M3-KI mice were protected against the development of abnormal bronchial responsiveness appeared to be unrelated to the number of inflammatory cells (eosinophils, lymphocytes and neutrophils) recruited within the airways. This dissociation between airway inflammation and the degree of airway hyper-responsiveness has been previously reported in various studies including observations in asthmatic patients (35) as well as in animal models of allergic inflammatory airway disease (36) (37) (38) . Rather, we propose that in the lung, phosphorylation of the M3-mAChR is important in driving key asthmatic features, such as airway hyper-responsiveness, in part via M3-mAChR phosphorylation and RhoA-dependent signaling.
Since our M3-KI mouse line expressing G protein biased M3-mAChR mutant defined a novel role for M3-mAChR phosphorylation-dependent signaling in ASM contraction we reasoned that this mouse line could be used to investigate other M3-mAChR-mediated physiological responses and establish whether these were dependent on G protein or receptor phosphorylation/arrestin-dependent signaling. We therefore examined M3-mAChR mediated salivary secretion and weight gain and established that both of these responses were slightly up-regulated in M3-KI mice indicating that they were not dependent on receptor phosphorylation/arrestin signaling, but more likely dependent on G protein coupling. The loss of the phosphorylation-dependent desensitization of G proteinmediated signalling may be responsible for the modest but significant increase in weight and salivary secretion observed in M3-KI mice.
These physiological responses could be added to our previous studies demonstrating a predominant role for M3-mAChR phosphorylation/arrestin coupling in the regulation of insulin secretion (14) and learning and memory (15) , and G protein coupling in M3-mAChR regulation of p53 subcellular localisation and apoptosis (39, 40). By combining all these studies, we have generated a map of the physiological responses mediated by the M3-mAChR through either G protein or receptor phosphorylation/arrestin-dependent signaling ( Figure 5E ).
This map has allowed us, for the first time, to make a prediction of the likely physiological outcomes of a biased GPCR ligand. Thus, an M3-mAChR drug-like ligand showing stimulus bias toward receptor phosphorylation and arrestin signaling would preferentially engage physiological signaling pathways that would promote changes in insulin secretion, impact on learning and memory, and regulate bronchoconstriction ( Figure 5F ). This same ligand would not be expected to have a substantial impact on salivary secretion, weight gain and mechanisms associated with cell survival (Figure 5F ). This analysis has considerable potential application in drug discovery where biased ligands can be designed to direct signaling towards those pathways that result in clinical efficacy and away from pathways that lead to adverse/toxic outcomes. Hence, by using a genetically modified mouse expressing a G protein biased receptor we are not only able to define the physiologically-relevant signaling pathways acting down-stream of a particular GPCR (in this case the M3-mAChR) but also determine what type of signaling bias to design into ligands targeting that receptor in order to promote a particular physiological/therapeutic outcome. B. Rho activity in CHO cells expressing the wild type or the phospho-deficient M3-mAChR mutant in response to carbachol (CCh). Data represents the mean ± SEM (n=4). Data were analyzed using a two-way ANOVA; *P<0.05, **P<0.01. C-D. Phospho-myosin light chain 2 (Ser-19) (green) and smooth muscle α-actin (red) immune-reactivity in the airways of wild type (C) or M3-KI (D) mice stimulated with vehicle or CCh (100 μM; 10 min). DAPI (blue) was used to stain nuclei, and overlaid images are shown to the right. Also shown is an image of the same airway using an x63 objective. E-G. The data in A, C and D represent the mean ± SEM of n=6-11 mice and were analyzed using a two-way ANOVA; *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. E. Illustration of the physiologically relevant signaling pathways down-stream of the M3-mAChR. Some of the pathways activated by the M3-mAChR in heterologous systems are illustrated (i.e. PLC, ERK, PKD, JNK, PI3-K, Src, RhoA, PLA 2 and p53). In this study we used a mutant mouse strain (M3-KI) expressing a G protein biased variant of the M3-mAChR to assign those physiological responses that were down-stream of either G protein signaling (green arrows) or receptor-phosphorylation and arrestin signaling (orange arrows). F. Such a map also allows for the rational design of biased ligands since our studies present a model by which the physiological/therapeutic outcome of biased ligands can be predicted. Thus, for the M3-mAChR, a ligand that is biased towards receptor-phosphorylation and arrestin signaling would preferentially impact on insulin release, learning and memory and bronchial contraction (orange arrows) whilst having potentially little impact on weight gain, salivary secretion and cell death pathways (grey arrows).
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